Development of immunotherapy against regulatory T cells targeting a new biomarker, VEGFR2

分析结直肠癌根治性手术切除患者肿瘤浸润VEGFR2+调节性T （Treg）细胞数量与预后的关系。肿瘤浸润的VEGFR2+FOXP3+Treg细胞数量是结直肠癌的独立预后因素。这些结果表明VEGFR2+ Treg可能是一个有效的治疗靶点。体外实验中，蛋白结合多糖、巴昔单抗、Cox-2抑制剂和贝伐单抗均可显著降低Treg数量。使用basiliximab消耗Treg后诱导的活化T淋巴细胞显示对癌细胞的细胞毒性增加。

Relation between the number of tumor-infiltrated VEGFR2+ regulatory T (Treg) cells and prognosis in colorectal cancer patients with curative surgical resection was analyzed. The number of tumor-infiltrated VEGFR2+FOXP3+Treg cells was an independent prognostic factor for colorectal cancer. These results indicate the validity that VEGFR2+ Treg could be a therapeutic target. In vitro experiment, protein-bound polysaccharide, basiliximab, Cox-2 inhibitor and bevacizumab significantly reduced Treg number. Activate T lymphocytes induced after the depletion of Treg using basiliximab showed the increase of cytotoxicity against cancer cells.